Tirzepatide 10mg Lyophilized Vial | Premium Dual GIP & GLP-1 Receptor Agonist

Upregulate your metabolic and endocrine research protocols with Alluvi Labs’ ultra-pure Tirzepatide 10mg lyophilized vial. Tirzepatide is a chemically modified 39-amino acid peptide structure designed to operate as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Highly documented across clinical and preclinical biochemical literature, this compound is extensively evaluated for its synergistic impact on pancreatic beta-cell activity, insulin secretion tracking, and systemic lipid metabolism models.
Our standalone 10mg units provide an exceptional baseline concentration for extended in vitro metabolic pathway mapping, cellular energy homeostasis tracking, and comparative cellular signaling assays.

Key Biochemical Characteristics & Purity Standards

To maintain absolute experimental integrity and ensure completely reproducible data sets, every batch of our Tirzepatide inventory undergoes rigorous solid-phase peptide synthesis followed by deep analytical validation:

• Verified Chemical Purity: Exceeds 98% composition confirmed directly via analytical High-Performance Liquid Chromatography (HPLC) profiles.
  
• Dual Agonist Structure: Synthesized based on the native GIP sequence, incorporating a C20 fatty diacid moiety to maximize biological half-life and stabilize receptor binding properties during evaluation.
  
• Visual Baseline Check: Lyophilized into a crisp, dense white uniform cake, serving as an immediate visual validation of uncompromised, moisture-free structural state.
  
• Atmospheric Protection: Vacuum-sealed under an inert gas layer inside durable glass laboratory vials to safeguard against premature hydrolytic cleavage or atmospheric oxidation.

Investigated Preclinical Action Channels

In peer-reviewed research tracking metabolic homeostasis, glycemic management, and cellular fat regulation, the Tirzepatide sequence demonstrates a dynamic array of biological vectors:

1. Synergistic Receptor Activation: Research indicates that the compound binds simultaneously to both GIP and GLP-1 receptors, triggering downstream cyclic AMP (cAMP) accumulation to analyze enhanced insulin secretion dynamics under high-glucose baselines.
   
2. Glucagon Suppression & Hepatic Regulation: Investigated for its capacity to reduce inappropriate glucagon secretion during assays, supporting secondary cellular mechanisms that regulate hepatic glucose production.
   
3. Adipocyte Homeostasis & Lipid Cleansing: Studies evaluate its structural role in altering lipid storage and energy expenditure pathways, looking at how the dual structural binding affects fat accumulation at the cellular level.

Product Specification Reference Table

Specification Parameter	Laboratory Standard Value
CAS Number	2023170-55-4
Molecular Formula	C225H348N48O68
Taste / Odor Profile	Odorless / Non-flavored Raw (Analytical Powder)
Total Active Content	10mg Lyophilized Powder
Solubility Profile	Freely Soluble in Sterile Water / Physiological Saline

🔬 Preclinical Research Notice

This chemical matrix is synthesized strictly for in vitro laboratory analysis, endocrine tracking, and animal metabolic research models. It is absolutely not intended, authorized, or safe for human therapeutic injection, weight loss management, dietary intake, or consumer application. All handling must be managed exclusively by qualified laboratory technicians.